Iressa reborn in US, after EU
https://www.reuters.com/article/latestCrisis/idUSN14444296
Well, TLN combo test fully makes senses now. Iressa re-approved in EU, expanded market in Asia due to growing pharm industry in China India.
Now, looks like Iressa to be reborn in US.
AstraZeneca has now the cash flow to buy a complementary product like TLN-4601.
Would make a perfect match and perfect sense.
Good business strategy to expand on current (new) market.
ASCO was the final unknown to takeover. I guess buyer has now everything they need to finalized the transaction.
4601 is the only product capable of expanding current market to 1st generation cancer drug and fight off new competition from Exelixis-Bristol-Myers-Squid.
What more do you want?
I like the new silence. At least, people posting are posting stuff about TLN not about each other.
Bashing has become repetitive and more more groundless due to news flow.